The Epilepsy Foundation of America recently supported the approval of Epidiolex at the FDA’s Peripheral and Central Nervous System Drug Advisory Committee. Based on this testification, the FDA Advisory Committee unanimously voted in favor of Epidiolex to treat Dravet syndrome and Lennox-Gastaut syndrome. This is the first time that the FDA advisory committee has recommended the approval of a cannabidiol drug.
The Epilepsy Foundation is a leading national voluntary health organization of the United States. It works for the welfare of 3.4 million patients with seizures and epilepsy disorders.
Epilepsy is a neurological disorder that affects people of all age groups. The medical condition causes epileptic seizures, which can be brief and undetectable for prolonged periods with vigorous shivering. These seizures affect a number of mental and physical functions of the human body. Around 1 in 26 Americans suffer from epilepsy at some point in their lives.
On the other hand, Dravet syndrome is a rare type of epilepsy that is intractable. The lifelong condition affects infants and thus delays development. It even raises the chances of premature death. It is highly treatment-resistant and causes frequent and prolonged seizures.
The epilepsy industry in the United States accounted for 4,007,027 cases in 2016. The industry is currently suffering from insufficient effective treatments. This is because the existing solutions provide no seizure control. These treatments also have adverse effects on the cognitive ability, memory, and mood of patients.
Despite several research advancements, the industry still lacks an effective solution for epilepsy and seizures. Many patients are living with the continual risk of serious injuries, and even death, from intractable and rare seizure disorders. However, the recent developments on Epidiolex are raising hope for epileptic patients.
In addition to this, the new recommended drug is effective against Lennox-Gastaut syndrome. This is a pediatric epilepsy syndrome. The condition causes multiple types of seizures, cognitive impairment, and abnormal results on the electroencephalogram. Besides this, it also causes a high risk of fatal injuries and uncontrollable seizures.
Epidiolex is derived from a purified form of cannabinoid found in medical cannabis. The drug is non-psychoactive in nature and holds therapeutic values to treat epilepsy and seizures.